Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lenadogene Nolparvovec
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GenSight Reports Five-Year Efficacy Data on LUMEVOQ Gene Therapy
Details : Lumevoq (lenadogene nolparvovec) is a recombinant rAAV2/2 investigational gene therapy containing the wild-type ND4 gene. It is being evaluated for the treatment of leber hereditary optic neuropathy.
Product Name : Lumevoq
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 12, 2025
Lead Product(s) : Lenadogene Nolparvovec
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lenadogene Nolparvovec
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GenSight Biologics Submits LUMEVOQ® Dossier to ANSM for Early Access in France
Details : Lumevoq (lenadogene nolparvovec) is a recombinant adeno-associated viral vector serotype 2, investigational gene therapy being evaluated for the treatment of leber hereditary optic neuropathy.
Product Name : Lumevoq
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 13, 2024
Lead Product(s) : Lenadogene Nolparvovec
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lenadogene Nolparvovec
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GenSight Confirms Efficacy and Safety Of LUMEVOQ® Four Years Post-Injection
Details : Lumevoq (lenadogene nolparvovec) is an investigational gene therapy using a recombinant adeno-associated viral vector for the treatment of Leber hereditary optic neuropathy.
Product Name : Lumevoq
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 20, 2024
Lead Product(s) : Lenadogene Nolparvovec
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lenadogene Nolparvovec
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lumevoq® (lenadogene nolparvovec) targets LHON by leveraging a mitochondrial targeting sequence proprietary technology platform, allows it to specifically address defects inside the mitochondria using an AAV vector.
Product Name : Lumevoq
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 13, 2023
Lead Product(s) : Lenadogene Nolparvovec
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GS030
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GS030 delivered via a single intravitreal injection, introduces a gene encoding for a light-sensitive protein (ChrimsonR-tdT) into retinal ganglion cells, making them responsive to light and bypassing photoreceptors killed off by diseases such as retinit...
Product Name : GS030
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 13, 2023
Lead Product(s) : GS030
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lenadogene Nolparvovec
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Safety findings at 5 years post-injection were consistent with previous readouts, which concluded that LUMEVOQ (GS010/lenadogene nolparvovec) is well-tolerated, no SAE were recorded among LUMEVOQ®-treated eyes, and no discontinuations occurred due to oc...
Product Name : Lumevoq
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
July 20, 2022
Lead Product(s) : Lenadogene Nolparvovec
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lenadogene Nolparvovec
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Safety findings at 4 years post-injection were consistent with previous readouts, which concluded that LUMEVOQ (lenadogene Nolparvovec) is well-tolerated with no serious adverse events were recorded among LUMEVOQ treated eyes, and no discontinuations occ...
Product Name : Lumevoq
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 24, 2022
Lead Product(s) : Lenadogene Nolparvovec
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lenadogene Nolparvovec
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The REFLECT trial’s demonstration of a sustained, significant and safe improvement in visual acuity for LHON patients treated bilaterally with LUMEVOQ provides additional impetus for our push to gain regulatory approval.
Product Name : Lumevoq
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 14, 2021
Lead Product(s) : Lenadogene Nolparvovec
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lenadogene Nolparvovec
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LUMEVOQ® (GS010; lenadogene nolparvovec) targets Leber Hereditary Optic Neuropathy (LHON) by leveraging a mitochondrial targeting sequence (MTS) proprietary technology platform.
Product Name : Lumevoq
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 30, 2021
Lead Product(s) : Lenadogene Nolparvovec
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lenadogene Nolparvovec
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GenSight submitted the MAA based on the benefit-risk balance established by results from a Phase-I/IIa study, two pivotal Phase-III efficacy studies and the long-term follow up study of RESCUE and REVERSET to demonstrate the efficacy of LUMEVOQ®.
Product Name : Lumevoq
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 15, 2020
Lead Product(s) : Lenadogene Nolparvovec
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable